The National Institute for Health and Clinical Excellence has recommended that bevacizumab, sorafenib, sunitinib and temsirolimus should not be treatment options for advanced or metastatic renal cell carcinoma.

The initial decision, which is subject to further consultation, was criticised by groups including Cancer Research UK.

See the NICE consultation documents at www.nice.org.uk

Topics